Diabetes, obesity & metabolism

Safety and How the Body Processes the UBT251 Injection Acting on Metabolism-Related Receptors: A Early-Stage Controlled Study

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

UBT251 is a novel triple agonist peptide targeting three hormonal receptors.

  • The study assessed the safety and tolerability of UBT251 in human subjects.
  • Pharmacokinetic characteristics of UBT251 were evaluated, indicating how the drug is absorbed and processed in the body.
  • Pharmacodynamic effects were also assessed, reflecting the drug's impact on biological functions related to its targets.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

Nov '22
LY3437943, a new drug activating three hormone receptors, tested in people with type 2 diabetes in a controlled early-stage trial with increasing doses
top 1% journal
cited by 190 papers
randomized controlled trial
Jun '25
Safety, body responses, and drug behavior of amycretin, a new combined GLP-1 and amylin receptor medicine, in a first human trial
top 1% journal
cited by 25 papers
randomized controlled trial
Oct '18
Safety and effectiveness of LY3298176, a new drug targeting two hormone receptors, in people with type 2 diabetes: a controlled phase 2 trial
top 1% journal
cited by 753 papers
randomized controlled trial
Dec '25
Long-acting GIPR activator LY3537021 lowers body weight and fasting blood sugar in type 2 diabetes patients
top 5% journal
randomized controlled trial
Jun '23
Retatrutide, a drug targeting three hormone receptors, for people with type 2 diabetes in a controlled US clinical trial
top 1% journal
cited by 367 papers
randomized controlled trial
Nov '18
LY3298176, a new drug that activates two hormone receptors to treat type 2 diabetes: from discovery to early clinical testing
top 5% journal
cited by 763 papers
randomized controlled trial
Apr '26
Safety and body effects of KN069, a drug targeting two hormone receptors, in overweight and obese men
journal article
May '24
Safety, body effects, and how TG103 works in overweight or obese participants in a controlled early-stage study
top 5% journal
cited by 5 papers
randomized controlled trial
Jun '25
Amycretin, a new drug activating appetite and blood sugar control receptors, tested by injection in an early clinical trial
top 1% journal
cited by 45 papers
randomized controlled trial

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #54
GLP-1 drugs don't build habits — and that gap is costing patients their results
5 days ago7 studies
issue #53
Semaglutide slowed aging and extended lifespan in older female mice
1 week ago7 studies
issue #52
GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes
2 weeks ago7 studies
issue #51
Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes
3 weeks ago7 studies
issue #50
A once-daily pill beat placebo on weight loss — and it wasn't semaglutide
4 weeks ago7 studies
issue #49
GLP-1 drugs work even without weight loss — and scientists are finally mapping why
5 weeks ago7 studies
issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
6 weeks ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
7 weeks ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
8 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief